# Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years

> **NCT03610464** · PHASE4 · COMPLETED · sponsor: **Tris Pharma, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Amphetamine Extended Release Suspension [Dyanavel]

## Key facts

- **NCT ID:** NCT03610464
- **Lead sponsor:** Tris Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-07
- **Primary completion:** 2018-05-23
- **Final completion:** 2018-05-23
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2019-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03610464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03610464, "Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03610464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*